Table 3.

The serum level of IL-6, TGF-β, and IL-17 in different clinic pathological parameters of patients with breast cancer

	IL-6 [pg/ml]			TGF-β [pg/ml]			IL-17 [pg/ml]
	Mean ±SEM	Median	p	Mean ±SEM	Median	p	Mean ±SEM	Median	p
Lymphatic invasion
Negative	4.89 ±0.88	3.37	NS	120.9 ±13.31	111.8	NS	9.38 ±0.97	7.69	NS
Positive	6.24 ±1.19	4.81		135.8 ±16.76	124.5		10.13 ±1.15	8.63
Vascular invasion
Negative	5.53 ±0.87	3.93	NS	125.3 ±12.48	111.8	NS	9.69 ±0.92	7.69	NS
Positive	4.99 ±1.09	3.47		130.9 ±17.64	128.7		9.56 ±0.97	8.99
Perineural invasion
Negative	5.04 ±0.86	3.47	NS	125.1 ±12.98	116.0	NS	10.1 ±0.77	7.69	NS
Positive	6.65 ±1.45	4.81		138.9 ±19.92	126.6		9.01 ±0.87	8.41
ER
Negative	3.67 ±0.26	3.47	NS	95.37 ±13.35	90.62	NS	9.87 ±1.33	7.40	NS
Positive	5.83 ±0.89	4.43		147.8 ±14.64	143.6		10.07 ±0.97	8.34
PR
Negative	5.10 ±1.14	3.74	NS	108.5 ±15.25	103.3	NS	10.40 ±1.23	8.4	NS
Positive	4.85 ±0.54	3.53		135.3 ±14.36	116.0		9.53 ±0.97	7.69
HER-2
Negative	5.76 ±0.94	4.43	NS	109.4 ±18.05	99.08	NS	9.72 ±1.17	9.85	NS
Positive	5.06 ±0.99	3.32		141.4 ±16.56	149.9		10.10 ±1.16	8.12
Necrosis
Negative	6.66 ±1.45	3.71	NS	124.6 ±15.62	116.0	NS	9.43 ±0.98	8.12	NS
Positive	4.30 ±0.36	3.98		135.7 ±14.88	122.4		10.15 ±1.23	8.63
Calcification
Negative	6.33 ±1.16	4.11	NS	135.4 ±12.05	128.7	NS	10.19 ±1.05	8.41	NS
Positive	4.16 ±0.44	3.53		121.7 ±22.08	94.85		9.195 ±1.19	7.40
Involvement
Right	5.11 ±0.64	3.95	NS	137.7 ±17.83	116.0	NS	9.41 ±1.05	8.12	NS
Left	5.68 ±1.24	3.53		118.8 ±11.98	122.4		9.92 ±1.08	7.83
Grade
Low	5.80 ±0.91	4.14	NS	126.3 ±12.78	111.8	NS	8.94 ±0.82	7.40	NS
High	4.18 ±0.76	3.47		138.8 ±16.12	133.0		11.35 ±1.35	9.27
Stage
Early	4.84 ±0.67	3.71	NS	120.2 ±11.24	111.8	NS	9.26 ±0.86	7.40	NS
Late	7.45 ±2.11	4.59		152.4 ±23.26	154.2		10.92 ±1.16	9.27
Metastasis
Negative	5.46 ±0.72	3.90	NS	125.2 ±10.48	113.9	NS	9.52 ±0.75	7.83	NS
Positive	3.20 ±0.58	3.05		193.5 ±22.77	198.8		11.62 ±1.72	11.51

NS – not significant